1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23096
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPallis, A. G.en
dc.contributor.authorVoutsina, A.en
dc.contributor.authorKalikaki, A.en
dc.contributor.authorSouglakos, J.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorMurray, S.en
dc.contributor.authorKoutsopoulos, A.en
dc.contributor.authorTripaki, M.en
dc.contributor.authorStathopoulos, E.en
dc.contributor.authorMavroudis, D.en
dc.contributor.authorGeorgoulias, V.en
dc.date.accessioned2015-11-24T19:30:27Z-
dc.date.available2015-11-24T19:30:27Z-
dc.identifier.issn0007-0920-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23096-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Agents/therapeutic useen
dc.subjectBinding Sites/geneticsen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathologyen
dc.subjectDNA Mutational Analysisen
dc.subjectDisease Progressionen
dc.subjectFemaleen
dc.subjectGene Frequencyen
dc.subjectGenotypeen
dc.subjectHumansen
dc.subjectKaplan-Meier Estimateen
dc.subjectLung Neoplasms/*drug therapy/genetics/pathologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subject*Mutationen
dc.subjectPrognosisen
dc.subjectProtein Kinase Inhibitors/therapeutic useen
dc.subjectQuinazolines/*therapeutic useen
dc.subjectReceptor, Epidermal Growth Factor/*geneticsen
dc.subjectTime Factorsen
dc.subjectTreatment Outcomeen
dc.title'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung canceren
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1038/sj.bjc.6604068-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18000506-
heal.identifier.secondaryhttp://www.nature.com/bjc/journal/v97/n11/pdf/6604068a.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstract'Classical' mutations in the EGFR tyrosine kinase domain (exons 18, 19 and 21) have been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC. The aim of the current study was to evaluate whether other than the classical G719X, DEL19 and L858R mutations of EGFR confer sensitivity to TKIs. Genomic DNA was extracted from microdissected formalin-fixed paraffin-embedded tumour tissue from 86 patients treated with gefitinib. Exons 18, 19 and 21 were amplified and subjected to direct sequencing. Eleven (13%) patients harboured the classical exon's 18, 19 and 21 mutations, while 14 (16%) had 'other' variants. There was a significantly higher percentage of 'never-smoker' patients with 'classical' EGFR mutations (P=0.002). Among patients with 'classical' mutations 3 patients achieved PR and 7 SD, while in the 'other' mutations group 10 patients had SD as best response. In the wild-type group, there were 3 patients with PR and 25 with SD. Median TTP was 16, 64 (P=0.002) and 21 weeks and median survival was 36, 78 and 67 weeks for patients with wild-type, 'classical' and 'other' EGFR mutations, respectively. The clinical relevance of 'other' EGFR mutation variants remains uncertain and requires further assessment in a prospective study.en
heal.journalNameBr J Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Pallis-2007-'Classical' but not.pdf147.32 kBAdobe PDFView/Open
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons